The pro-resolving lipid mediator Maresin 1 ameliorates pain responses and neuroinflammation in the spared nerve injury-induced neuropathic pain: A study in male and female mice

Data de publicação:

Autores da FMUP

  • Teresa Maria De Jesus Teixeira De Sousa

    Autor

  • Dora Raquel Da Silva Pinho

    Autor

Participantes de fora da FMUP

  • Teixeira Santos, L
  • Martins, S
  • Albino-Teixeira, A

Unidades de investigação

Abstract

Specialized pro-resolving mediators (SPMs) have recently emerged as promising therapeutic approaches for neuropathic pain (NP). We evaluated the effects of oral treatment with the SPM Maresin 1 (MaR1) on behavioral pain responses and spinal neuroinflammation in male and female C57BL/6J mice with spared nerve injury (SNI)-induced NP. MaR1, or vehicle, was administered once daily, on post-surgical days 3 to 5, by voluntary oral intake. Sensory-discriminative and affective-motivational components of pain were evaluated with von Frey and place escape/avoidance paradigm (PEAP) tests, respectively. Spinal microglial and astrocytic activation were assessed by immunofluorescence, and the spinal concentration of cytokines IL-1 & beta;, IL-6, IL-10, and macrophage colony-stimulating factor (M-CSF) were evaluated by multiplex immunoassay. MaR1 treatment reduced SNI-induced mechanical hypersensitivity on days 7 and 11 in both male and female mice, and appeared to ameliorate the affective component of pain in males on day 11. No definitive conclusions could be drawn about the impact of MaR1 on the affective-motivational aspects of pain in female mice, since repeated suprathreshold mechanical stimulation of the affected paw in the dark compartment did not increase the preference of vehicle-treated SNI females for the light side, during the PEAP test session (a fundamental assumption for PAEP's validity). MaR1 treatment also reduced ipsilateral spinal microglial and astrocytic activation in both sexes and marginally increased M-CSF in males, while not affecting cytokines IL-1 & beta;, IL-6 and IL-10 in either sex. In summary, our study has shown that oral treatment with MaR1 (i) produces antinociception even in an already installed peripheral NP mouse model, and (ii) this antinociception may extend for several days beyond the treatment time-frame. These therapeutic effects are associated with attenuated microglial and astrocytic activation in both sexes, and possibly involve modulation of M-CSF action in males.

Dados da publicação

ISSN/ISSNe:
1932-6203, 1932-6203

PLoS ONE  Public Library of Science

Tipo:
Article
Páginas:
-
Link para outro recurso:
www.scopus.com

Citações Recebidas na Scopus: 4

Documentos

  • Não há documentos

Métricas

Filiações mostrar / ocultar

Keywords

  • PLACE ESCAPE/AVOIDANCE BEHAVIOR; ACTIVATED PROTEIN-KINASE; RAT MODEL; HYPERSENSITIVITY; RESOLUTION; MOUSE; ANXIETY; INFLAMMATION; MINOCYCLINE; INHIBITION

Financiamento

Proyectos asociados

Unresolved inflammation and endothelitis in severe COVID-19 patients: identification of risk stratification biomarkers and therapeutic targets. (severe COVID-19)

Investigador Principal: Teresa Maria de Jesus Teixeira de Sousa

Estudo Clínico Académico (Severe COVID-19) . FCT . 2020

Endocan: a novel biomarker for risk stratification, prognosis, and therapeutic monitoring in human cardiovascular and renal diseases

Investigador Principal: Teresa Maria de Jesus Teixeira de Sousa

Estudo Clínico Académico (Endocan) . 2020

Renal renin-angiotensin system activation in acute heart failure and its association with endothelial dysfunction, inflammation and oxidative stress.

Investigador Principal: Teresa Maria de Jesus Teixeira de Sousa

Estudo Clínico Académico (Renal) . 2021

Urinary cysteinyl leukotrienes as biomarkers of endothelial activation, inflammation and oxidative stress and their relationship with organ dysfunction in human septic shock

Investigador Principal: Teresa Maria de Jesus Teixeira de Sousa

Estudo Clínico Académico . 2021

Evaluation of 11-dehydro-thromboxane B2 as a biomarker of severity and putative therapeutic target in human acute heart failure and cardiogenic shock

Investigador Principal: Teresa Maria de Jesus Teixeira de Sousa

Estudo Clínico Académico . 2022

Endothelial dysfunction in different stages of diseases severity of COVID-19: focus on endocan and arterial hypertension

Investigador Principal: Teresa Maria de Jesus Teixeira de Sousa

Estudo Clínico Académico . 2022

Evaluation of urinary cysteinyl leukotrienes as biomarkers of severity and putative therapeutic targets in COVID-19 patients

Investigador Principal: Teresa Maria de Jesus Teixeira de Sousa

Estudo Clínico Académico . 2022

Citar a publicação

Partilhar a publicação